You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The team said it will partner with startup Early Diagnostics to commercialize the assay, which integrates DNA methylation analysis and computational technology.
While orders of its Liquid GPS are increasing, Soon-Shiong expressed frustration with the slow pace of reimbursement and urged investor patience.
The solution uses machine learning to pare down somatic variant lists, simplifying the task of manually reviewing the output of sequence analysis pipelines.
Use of the Oncomine Focus Assay led to an expansion of genomic profiling for all guideline-recommend alterations and the identification of a broad set of clinically relevant targets.
The company will use its NeoType Discovery Panel for the trial. The panel assesses 320 cancer-related genes in solid tumors, hematologic malignancies, and advanced sarcomas.
The move is precipitated by CMS's decision to grant national coverage to NGS companion diagnostics when they're approved by the FDA.
With the new five-year funding, patients across Australia with rare or less common cancers will be able to access the program through a network of eight cancer centers.
New genetic studies are providing insights into the molecular changes that occur as benign moles transition to melanoma and spread to other parts of the body by metastasis.
Under a definitive merger agreement, Roche will acquire outstanding shares of Foundation's common stock for $137 per share.
A targeted sequencing analysis of 42 pancreatic ductal adenocarcinoma has uncovered prognostically-relevant germline mutations in 29 percent of sporadic cases.
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.